BRUSSELS, REDBANK, New Jersey and MELBOURNE Australia, Nov. 4, 2011
/CNW/ - Global leader in healthcare protection and safety solutions
lands CE Mark for GAMMEX® Powder-Free Gloves with AMT Antimicrobial
One year after its introduction in Australia, Ansell today announced it
is kicking off a European launch program of their new GAMMEX®
Powder-Free glove with AMT Antimicrobial Technology.
The GAMMEX® Powder-Free glove with AMT Antimicrobial Technology is the
first surgical glove which incorporates a proprietary antimicrobial
coating to provide an additional level of protection to surgical staff
against viruses and bacteria, in the event of a breach during surgery.
Ever since its introduction last year in Australia, this unique Ansell
innovation received overall industry acclaim and is being considered a
significant technical breakthrough in terms of bringing about a change
from passive protection to active protection.
The gloves, made of NRL, provide the same feel, sensitivity, flexibility
and dexterity as conventional gloves when manipulating and handling
instruments. The main difference is the active antimicrobial layer
which contains chlorhexidine gluconate (CHG). This technology can
provide ongoing antiviral and antibacterial protection against HIV,
hepatitis C and infectious bacteria.
"Improving healthcare systems around the world and an increasing
awareness by healthcare workers that gloves offer an effective
protection against contamination from bacteria and viruses have been a
key driver for the rapid expansion of the medical gloves industry," says Magnus Nicolin, CEO of Ansell Limited.
"This unique and proprietary AMT Antimicrobial Technology reduces
surgical staff risks of exposure to blood-borne pathogens through a
higher level of protection," he continues. "Just as the introduction of the first surgeon gloves significantly
decreased surgical site infections, Ansell has great expectations that
this glove will take patient protection to another level. We will now
be focusing our research efforts on clinically quantifying the
potential that this surgical glove innovation has on reducing the
number of Hospital Acquired Infections (HAI's) and any costs
associated," he concludes.
First launched in Australia and Europe, Ansell's AMT Antimicrobial
Technology will progressively be rolled out in all Ansell markets. * In
clinical and laboratory tests, GAMMEX® Powder-Free with AMT killed at
least 99% of invading HIV and HCV (hepatitis C) surrogate pathogens,
the two main viruses that concern surgeons. In addition, clinical
testing has shown that the gloves kill over 99.7% of eight common
infectious bacteria (gram-positive, gram-negative and drug-resistant
bacteria) and kill over 99.99% of staphylococcus aureus.
GAMMEX® Powder-Free Gloves with AMT Antimicrobial Technology are not
proven to protect against blood-borne infections where the skin is
broken, cut or punctured. GAMMEX® Powder-Free Gloves with AMT
Antimicrobial Technology contain natural rubber latex, which may cause
Australia Patent No. 703926 and New Zealand Patent No. 556353. AU and
worldwide patents pending.
Ansell, ® and ™ are trademarks owned by Ansell Limited or one of its
affiliates. © 2011 Ansell Limited. All rights reserved.
SOURCE Ansell Healthcare
For further information:
Media, Wouter Piepers, GCC-Ansell, Tel: (00322) 5287400, email@example.com, US - Jeff Picarello, Edelman PR, Tel:(1212)7048244, firstname.lastname@example.org, I.R., David Graham, I.R.-Ansell, Tel:(613)92707215, email@example.com